Biomarker testing helps connect patients with the right treatment at the right time.
ACS CAN and partners support SB 989 (Huffman) / HB 3188 (Bonnen) to ensure more Texans can benefit from this important testing.
What is Biomarker Testing?
- In cancer care, biomarkers are often used to help determine the best treatment for a patient.
- A “biomarker” is a sign of a normal biological process, disease or abnormal function that can be measured in blood, tissue or bodily fluid.
- Biomarker testing is the analysis of a patient’s tissue, blood or other biospecimen for the presence of a biomarker.
Policy action needed to ensure more Texans benefit.
- Not all communities are benefiting from the latest advancements in biomarker testing and precision medicine.
- Communities that have been excluded, including communities of color, individuals with lower socioeconomic status, rural communities, and those receiving care in non-academic medical centers are less likely to receive biomarker testing.
- Improving coverage for and access to biomarker testing across insurance types is key to reducing health disparities.
- Without action to expand coverage and access to biomarker testing, advances in precision medicine could increase existing disparities in cancer outcomes by race, ethnicity, income, and geography.
- Insurance coverage for biomarker testing is failing to keep pace with innovations and advancements in treatment.